Sensitivity pattern of Gram negative bacteria to the new β-lactam/β-lactamase inhibitor combination: Cefepime/tazobactam
Amaç: Gram negative bakterilerde artan Karbapenem direnci araştırmacıları alternatif antibiyotik seçeneklerini araştırmaya yöneltti. Değişik ß-laktam/ß-laktamaz inhibitor (BL/BLI) kombinasyonları birçok ülkede karbapenemleri koruma stratejisi olarak kullanılmaktadır. Bu çalışmanın amacı sefepim/tazobaktam kombinasyonunun duyarlılık paternlerini araştırmak ve piperasilin/tazobaktam, sefoperazon/sulbaktam, sefepim ve karbapenem ile karşılaştırmaktır. Gereç ve yöntem: Güney Hindistan’da üçüncü basamak Onkoloji, Nöroşirurji ve Ortopedi merkezi olan Apollo İhtisas Hastanesinde Gram negative bakteri izolatlarının duyarlılık paternlerini inceleyen retrospektif bir araştırma yaptık. Bulgular: Bir yıllık sürede toplanan 1003 Gram negatif bakteri suşundan % 60,5’i piperasilin/tazobaktama, % 46,2’si sefepime, %80,4’ü sefepime/tazobaktama, %71,3’ü sefoperazon/sulbaktama, %79,1’i imipeneme ve %78,2’si meropeneme duyarlı idi. Tazobaktam eklenmesi ile sefepime olan duyarlılık, tüm gram negatif bakteriler dikkate alındığında %46,2’den %80,4’e; E. coli’de %34,4’den %87,9’a, Klebsiella’da %42,3’den %81,0’e, Pseudomonas’da %72,0’den %81,4’e ve Acinetobacter’de %17’2’den %54,5’e yükseldi. Sonuç: Sefepim/tazobaktam, çalışmaya alınan diğer BL/BLI kombinasyonlarına göre daha iyi bir invitro duyarlılık profili gösterdi. Bu invitro verilerin klinik çalışmalarla teyit edilmesi gerekmektedir.
Yeni β-laktam/β-laktamaz inhibitorü kombinasyonuna Gram negatif bakterilerin duyarlılık
Objectives: Increasing prevalence of carbapenem-resistant Gram negative bacteria has prompted researchers to explore alternative antibiotic options. Different ß-lactam/ß-lactamase inhibitor (BL/BLI) combinations are used in many countries, as a carbapenem saving strategy. The purpose of our study was to evaluate the sensitivity pattern of cefepime/tazobactam combination in comparison to piperacillin/tazobactam, cefoperazone/sulbactam, cefepime and carbapenem agents.Materials and methods: We conducted retrospective analysis of the sensitivity pattern of Gram negative bacterial isolates in Apollo Speciality Hospital; a 300 bedded, tertiary care Oncology, Neurosurgical and Orthopaedic Centre in South India.Results: Out of the 1003 Gram negative, non-repetitive isolates collected over a period of one year; 60.5% were sensitive to piperacillin-tazobactam, 46.2% to cefepime, 80.4% to cefepime/tazobactam, 71.3% to cefoperazone-sulbactam, 79.1% to imipenem and 78.2% to meropenem. Addition of tazobactam increased the susceptibility of cefepime from 46.2% to 80.4% in gram negative isolates in general; from 34.4 to 87.9% in E. coli, from 42.3 to 81.0% to Klebsiella, from 72.0 to 81.4% in Pseudomonas and 17.2-54.5% to Acinetobacter.Conclusion: Cefepime/tazobactam provided a better invitro sensitivity profile than other BL-BLI combinations studied. This in vitro data needs to be confirmed by clinical studies.
___
- 1. Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-Lactam/β- Lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin Infect Dis 2012: 54:167-174.
- 2. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hegde A, Soman R. New Delhi Metallo-ß-lactamase (NDM-1) in Enterobacteriaceae: Treatment options with Carbapenems Compromised. J Assoc Physicians India 2010; 58:147-9.
- 3. Livermore DM ,Hope R, Mushtaq S, Warner M. Orthodox and unorthodox clavulanate combinations against extended spectrum ß lactamase producers. Clin Microbiol Infect 2008;14 Suppl 1:189-193.
- 4. Ghafur A, Nagvekar V, Thilakavathy S, Chandra, Gopalakrishnan R. An Indian Success story of Infection Control through Persuasive Diplomacy. Poster presented at 3rd World Healthcare Associated Infection Forum, June 2011, Annecy, France; Poster No.6.
- 5. Walsh TR ,Toleman MA, Jones RN. Comment on: Occurrence, prevalence and genetic environment of CTX-M ßlactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2007; 59:799-820
- 6. Rajini E, Sherwal BL, Anuradha .Detection of Extended-Spectrum β-lactamases in AmpC β-lactamase-Producing Nosocomial Gram-negative Clinical Isolates from a Tertiary Care Hospital in Delhi.Indian J Pract Doctor 2008 : 4.
- 7. Mouton JW et al. In Vitro Activity of Cefepime alone and in combination with Tazobactam against ESBL producers. Poster session presented at ICAAC 2010, 12- 15 Sept; Boston, USA; A- 2251
- 8. Clinical and Laboratory Standards Institute (2009). M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition. Wayne, PA: CLSI.
- 9. Clinical and Laboratory Standards Institute (2009). M100-S19. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Wayne, PA: CLSI
- 10. Paterson DL, Bonomo R. Extended-spectrum beta-lactamase: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
- ISSN: 2146-3158
- Başlangıç: 2011
- Yayıncı: Sağlık Araştırmaları Derneği